The Nationwide Most cancers Institute has awarded a $1.8 million grant to investigators on the College of California, Los Angeles (UCLA) Well being Jonsson Complete Most cancers Heart to assist the continued GARUDA trial (NCT04624256), which is assessing the predictive worth of genetic markers in figuring out which sufferers usually tend to expertise genitourinary (GU) toxicity following radiation remedy for prostate most cancers.1
Completion of the examine is anticipated for December 2028.
“Our objective is to enhance the post-treatment high quality of life for sufferers with prostate most cancers by predicting and stopping the hostile results of radiation remedy,” stated principal investigator Amar U. Kishan, MD, in a information launch on the examine.1 “This grant will enable us to broaden our analysis and convey us nearer to attaining that objective.”
Already, the staff of investigators has recognized the biomarker PROSTOX, which has proven the power to foretell GU toxicity following superior radiation remedy. With this grant, the staff plans to additional validate the predictive worth of PROSTOX and different mirSNP genetic markers which have proven promise in predicting toxicity from most cancers therapy.
“By understanding the mirSNP genetic markers that predispose sufferers to hostile negative effects from most cancers remedy we will tailor these therapies to attenuate hurt and maximize efficacy. This work has the potential to enhance the lives of numerous sufferers,” stated co-investigator Joanne B. Weidhaas, MD, PhD, MS, within the information launch.1 Weidhaas is a co-developer of the PROSTOX take a look at in addition to a professor of radiation oncology and vice chair and head of translational analysis at UCLA.
Preliminary knowledge from the GARUDA trial have been shared final 12 months on the 2023 American Society of Scientific Oncology Annual Assembly.2
General, knowledge confirmed that 98.8% of sufferers characterised as low threat for GU toxicity selected to proceed with stereotactic physique radiation remedy (SBRT), in contrast with solely 55.2% of sufferers categorized as excessive threat for toxicity (P < .001). In sufferers who had over 18 months of follow-up knowledge (n = 57), late GU toxicity better than grade 2 was noticed in 4.8% of sufferers categorized as low threat vs 27.3% of these categorized as excessive threat (P = .015).
In whole, the GARUDA trial has enrolled over 200 grownup sufferers with prostate most cancers who’re eligible to bear SBRT.3
Sufferers have been excluded from the trial in the event that they introduced with neuroendocrine or small cell carcinoma of the prostate, any proof of distant metastases, or had a historical past of Crohn illness, ulcerative colitis, or ataxia telangiectasia. Moreover, sufferers couldn’t have undergone prior whole-gland cryosurgery, high-intensity targeted ultrasound, brachytherapy of the prostate, or pelvic radiotherapy.2
All sufferers included within the examine will bear SBRT per customary of care (SOC), adopted by an evaluation of germline biomarkers with a non-prospectively validated biomarker panel. These sufferers who’re decided to be at low threat for toxicity with SBRT will proceed to obtain SBRT for 14 days. These decided to have a excessive threat for toxicity might be endorsed to obtain both conventionally fractionated radiotherapy over 63 to 70 days, average hypofractionated radiotherapy over 28 to 35 days, or to proceed to obtain SBRT over 14 days per SOC.
The first consequence measure for the examine is the incidence of late-grade 2 or larger physician-score GU toxicity, as assessed for as much as 5 years. Secondary consequence measures embrace 5-year biochemical recurrence-free survival, the speed of acute grade 2 or better GU and gastrointestinal physician-scored toxicity, and the change in patient-reported urinary, bowel, and sexual high quality of life.
Completion of the examine is anticipated for December 2028.3
References
1. Radiation oncologists awarded $1.8 million grant to advance personalised most cancers remedy. Information launch. College of California, Los Angeles (UCLA), Well being Sciences. July 3, 2024. Accessed July 11, 2024. https://www.newswise.com/articles/view/813586/
2. Weidhaas JB, Marco N, Steinberg ML, et al. Early findings from the GARUDA trial: The influence of a genetic signature of late radiation toxicity on prostate most cancers therapy resolution making. J Clin Oncol. 2023;41(suppl 16):5089. doi:10.1200/JCO.2023.41.16_suppl.50
3. Germline DNA-based radiosensitivity biomarker affect on toxicity following prostate radiotherapy, GARUDA trial (GARUDA). ClinicalTrials.gov. Final up to date March 12, 2024. Accessed July 11, 2024. https://clinicaltrials.gov/examine/NCT04624256
